Literature DB >> 28965698

Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease.

Jennifer A Ducie1, Ane Gerda Zahl Eriksson1, Narisha Ali1, Michaela E McGree2, Amy L Weaver2, Giorgio Bogani3, William A Cliby4, Sean C Dowdy4, Jamie N Bakkum-Gamez4, Robert A Soslow5, Gary L Keeney6, Nadeem R Abu-Rustum7, Andrea Mariani4, Mario M Leitao8.   

Abstract

OBJECTIVE: To determine if a sentinel lymph node (SLN) mapping algorithm will detect metastatic nodal disease in patients with intermediate-/high-risk endometrial carcinoma.
METHODS: Patients were identified and surgically staged at two collaborating institutions. The historical cohort (2004-2008) at one institution included patients undergoing complete pelvic and paraaortic lymphadenectomy to the renal veins (LND cohort). At the second institution an SLN mapping algorithm, including pathologic ultra-staging, was performed (2006-2013) (SLN cohort). Intermediate-risk was defined as endometrioid histology (any grade), ≥50% myometrial invasion; high-risk as serous or clear cell histology (any myometrial invasion). Patients with gross peritoneal disease were excluded. Isolated tumor cells, micro-metastases, and macro-metastases were considered node-positive.
RESULTS: We identified 210 patients in the LND cohort, 202 in the SLN cohort. Nodal assessment was performed for most patients. In the intermediate-risk group, stage IIIC disease was diagnosed in 30/107 (28.0%) (LND), 29/82 (35.4%) (SLN) (P=0.28). In the high-risk group, stage IIIC disease was diagnosed in 20/103 (19.4%) (LND), 26 (21.7%) (SLN) (P=0.68). Paraaortic lymph node (LN) assessment was performed significantly more often in intermediate-/high-risk groups in the LND cohort (P<0.001). In the intermediate-risk group, paraaortic LN metastases were detected in 20/96 (20.8%) (LND) vs. 3/28 (10.7%) (SLN) (P=0.23). In the high-risk group, paraaortic LN metastases were detected in 13/82 (15.9%) (LND) and 10/56 (17.9%) (SLN) (%, P=0.76).
CONCLUSIONS: SLN mapping algorithm provides similar detection rates of stage IIIC endometrial cancer. The SLN algorithm does not compromise overall detection compared to standard LND.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endometrial carcinoma; Lymphadenectomy; Sentinel node mapping

Mesh:

Year:  2017        PMID: 28965698     DOI: 10.1016/j.ygyno.2017.09.030

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  20 in total

Review 1.  Where Are We Going with Sentinel Lymph Node Mapping in Gynecologic Cancers?

Authors:  C Reneé Franklin; Edward J Tanner
Journal:  Curr Oncol Rep       Date:  2018-11-13       Impact factor: 5.075

2.  Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: surgical outcomes and hospital charges.

Authors:  Katherine I Stewart; Jarrod S Eska; Ross F Harrison; Rudy Suidan; Ann Abraham; Gary B Chisholm; Larissa A Meyer; Shannon N Westin; Nicole D Fleming; Michael Frumovitz; Thomas A Aloia; Pamela T Soliman
Journal:  Int J Gynecol Cancer       Date:  2020-01-06       Impact factor: 3.437

3.  Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy.

Authors:  Brooke A Schlappe; Amy L Weaver; Jennifer A Ducie; Ane Gerda Zahl Eriksson; Sean C Dowdy; William A Cliby; Gretchen E Glaser; Robert A Soslow; Kaled M Alektiar; Vicky Makker; Nadeem R Abu-Rustum; Andrea Mariani; Mario M Leitao
Journal:  Gynecol Oncol       Date:  2018-08-31       Impact factor: 5.482

4.  Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma.

Authors:  Derman Basaran; Shaina Bruce; Emeline M Aviki; Jennifer J Mueller; Vance A Broach; Karen Cadoo; Robert A Soslow; Kaled M Alektiar; Nadeem R Abu-Rustum; Mario M Leitao
Journal:  Gynecol Oncol       Date:  2019-11-16       Impact factor: 5.482

5.  ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2021-02       Impact factor: 4.064

6.  UPDATE ON SENTINEL LYMPH NODE MAPPING IN ENDOMETRIAL CANCER PATIENTS WITH A HIGH RISK FOR NODAL METASTASIS.

Authors:  Derman Basaran; Mario M Leitao
Journal:  Indian J Gynecol Oncol       Date:  2020-04-13

Review 7.  Controversies in the Management of Early-stage Serous Endometrial Cancer.

Authors:  Alyssa Larish; Andrea Mariani; Carrie Langstraat
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

8.  Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma.

Authors:  Jennifer J Mueller; Silvana Pedra Nobre; Kenya Braxton; Kaled M Alektiar; Mario M Leitao; Carol Aghajanian; Lora H Ellenson; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2020-04-01       Impact factor: 5.482

9.  Retrospective validation of the laparoscopic ICG SLN mapping in patients with grade 3 endometrial cancer.

Authors:  Andrea Papadia; Maria Luisa Gasparri; Anda P Radan; Chantal A L Stämpfli; Tilman T Rau; Michael D Mueller
Journal:  J Cancer Res Clin Oncol       Date:  2018-04-24       Impact factor: 4.553

Review 10.  Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers.

Authors:  Sandra Russo; Joan L Walker; Jay W Carlson; Jeanne Carter; Leigh C Ward; Allan Covens; Edward J Tanner; Jane M Armer; Sheila Ridner; Sandi Hayes; Alphonse G Taghian; Cheryl Brunelle; Micael Lopez-Acevedo; Brittany A Davidson; Mark V Schaverien; Sharad A Ghamande; Michael Bernas; Andrea L Cheville; Kathleen J Yost; Kathryn Schmitz; Barbara Coyle; Jeannette Zucker; Danielle Enserro; Stephanie Pugh; Electra D Paskett; Leslie Ford; Worta McCaskill-Stevens
Journal:  Gynecol Oncol       Date:  2020-11-04       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.